Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Trial Profile

Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Expanded access; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Mar 2017 Results (n=315) of KEYNOTE-001,KEYNOTE-002, KEYNOTE-006 and one expanded acces phase II study assessing clinicopathological factors in PD-1 antibodies response published in the British Journal of Cancer.
    • 15 Nov 2016 Results of retrospective analysis from pooled data of this and other five studies (n=60) published in the Cancer.
    • 12 Oct 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top